Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Review · June 11, 2024

Durability of Intravitreal Anti-VEGF Agents and Evolution of Retreatment Criteria for Diabetic Macular Edema

Current Opinion in Ophthalmology


Additional Info

Disclosure statements are available on the authors' profiles:

Current Opinion in Ophthalmology
Enhanced durability and evolution of retreatment criteria of intravitreal antivascular endothelial growth factor agents for diabetic macular edema
Curr Opin Ophthalmol 2024 May 01;35(3)197-204, NK Mandava, AE Kuriyan, AC Ho, J Hsu, CD Regillo, MA Klufas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading